Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal The Indonesian Biomedical Journal Eduvest - Journal of Universal Studies
Primastari, Etis
Unknown Affiliation
Aerospace Engineering Biochemistry, Genetics & Molecular Biology Computer Science & IT Health Professions Neuroscience Public Health Social Sciences

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Clinicopathological Features of Ovarian Adult Granulosa Cell Tumor in Dr. Hasan Sadikin General Hospital Bandung from 2019 to 2025 Irma Melati, Ganda; Dewayani, Birgitta M.; Primastari, Etis
Eduvest - Journal of Universal Studies Vol. 5 No. 10 (2025): Eduvest - Journal of Universal Studies
Publisher : Green Publisher Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59188/eduvest.v5i10.52256

Abstract

Adult granulosa cell tumor (AGCT) is the most common ovarian sex cord–stromal tumor (SCST), comprising approximately 70% of cases. It is a low-grade malignant neoplasm with a tendency for late recurrence and metastasis. Tumor stage and rupture in stage I disease are the most important prognostic factors. This study aimed to describe the clinicopathological characteristics of AGCT patients treated at Dr. Hasan Sadikin General Hospital, Bandung, from 2019 to 2025. This observational analytic study included 46 women who underwent surgical resection and were histopathologically diagnosed with AGCT with documented International Federation of Gynecology and Obstetrics (FIGO) stage at Dr. Hasan Sadikin General Hospital between 2019 and 2025. Sampling was consecutive. Variables observed included age, FIGO stage, laterality, ascites, surgical procedures, tumor size, histopathological pattern, mitotic count, necrosis, lymphovascular invasion, endometrial pathology, and adjuvant chemotherapy. Data were analyzed descriptively. The mean age of patients was 47 years (range 19–63). The mean tumor size was 23.7 cm, and most tumors (82.6%) measured ≥10 cm. Nearly all were unilateral (97.8%), with slight predominance in the right ovary (54.3%). Ascites was present in 56.5% of patients. Histologically, 89.1% exhibited multiple admixed growth patterns with low mitotic activity. Necrosis and lymphovascular invasion were observed in 30.4% and 17.4% of cases, respectively. Endometrial alterations were rare (6.5%). Stage distribution was 47.8% stage I, 2.2% stage II, 41.3% stage III, and 8.7% stage IV. Adjuvant chemotherapy was administered to 50% of patients, most frequently paclitaxel–carboplatin (60.8%).
Combined COX-2 and HER-2 Biomarker Profiling to Predict Neoadjuvant Chemoradiotherapy Response in Locally Advanced Rectal Cancer Susyanto, Terri Sandi; Lukman, Kiki; Purnama, Andriana; Utama, Marhendra Satria; Primastari, Etis
The Indonesian Biomedical Journal Vol 18, No 1 (2026)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v18i1.3959

Abstract

BACKGROUND: Locally advanced rectal cancer (LARC) is commonly treated with neoadjuvant chemoradiotherapy (nCRT), but highly variable response limits outcomes and highlights the need for predictive biomarkers. Cyclooxygenase-2 (COX‑2) and human epidermal growth factor receptor 2 (HER‑2) are overexpressed in a subset of colorectal cancers and are mechanistically linked to radioresistance. Both pathways are therapeutically targetable and exhibit molecular crosstalk, suggesting that combined assessment may improve prediction of nCRT response, but their combined predictive value in LARC remains unexplored. Therefore, this study was conducted to evaluate the association between COX‑2 and HER‑2 expression and radiotherapy response in patients with LARC.METHODS: This observational retrospective cohort study included 59 patients with stage II–III rectal adenocarcinoma treated with standardized nCRT. COX-2 and HER-2 expressions on pretreatment biopsies were assessed by immunohistochemistry, and radiologic response 4–8 weeks post nCRT dichotomized into good and poor responses using RECIST 1.1.RESULTS: High COX-2 expression was present in 67.8% of tumors and was associated with poor response (p<0.001; OR=10.08; 95% CI: 2.92–34.78). HER-2 positivity (32.2% of cases) was also associated with poor response (p=0.039; OR=4.28; 95% CI: 1.16–15.79). In multivariate analysis, high COX-2 (adjusted OR=0.110; p=0.002) and HER-2 positivity (adjusted OR=0.197; p=0.049) remained independent predictors of poor response. Tumors with combined COX-2 low/HER-2 negative and COX-2 high/HER 2 positive profiles showed good response rates of 86.7% and 13.3%, respectively, representing a 73.4% absolute difference.CONCLUSION: Since Low COX-2 expression and HER-2 negativity is mostly associated with good radiotherapy response, hence COX-2 and HER-2 might be independent molecular predictors of radiotherapy response in LARC, and combined biomarker profiling provides robust risk stratification that may guide treatment intensification or de escalation strategies.KEYWORDS: COX-2, HER-2, rectal cancer, radiotherapy response, biomarker, personalized medicine
Co-Authors Andriana Purnama, Andriana Birgitta M. Dewayani, Birgitta M. Irma Melati, Ganda Kiki Lukman Susyanto, Terri Sandi Utama, Marhendra Satria